Focused Wealth Management’s ADC Therapeutics ADCT Stock Holding History

Focused Wealth Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-300	Closed	-$498	–	219
2023 Q4	$498	Hold	300	–	–	﹤0.01%	903
2023 Q3	$269	Hold	300	–	–	﹤0.01%	954
2023 Q2	$645	Hold	300	–	–	﹤0.01%	935
2023 Q1	$585	Hold	300	–	–	﹤0.01%	925
2022 Q4	$1.15K	Hold	300	–	–	﹤0.01%	851
2022 Q3	$1K	Hold	300	–	–	﹤0.01%	802
2022 Q2	$2K	Hold	300	–	–	﹤0.01%	715
2022 Q1	$4K	Hold	300	–	–	﹤0.01%	696
2021 Q4	$6K	Hold	300	–	–	﹤0.01%	658
2021 Q3	$8K	Buy	+300	New	+$7.68K	﹤0.01%	627

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Focused Wealth Management's ADCT Position: Q1 2024 in Review

Focused Wealth Management sold out of ADC Therapeutics (ADCT) in Q1 2024, closing a stake of 300 shares — an estimated $498 sold.

Focused Wealth Management first reported a position in ADCT in Q3 2021 and held it in 10 quarters. The position peaked at $8K in Q3 2021. 36 funds tracked by Wall St. Rank hold ADCT as of Q1 2024.

Focused Wealth Management reported no remaining ADC Therapeutics position as of Q1 2024 after selling out during the quarter.
Focused Wealth Management sold 300 ADC Therapeutics shares in Q1 2024, an estimated $498.
Focused Wealth Management first reported a position in ADC Therapeutics in Q3 2021 and held it in 10 quarters.
Focused Wealth Management's ADC Therapeutics position peaked at $8K in Q3 2021.
36 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.